Drug resistant tuberculosis (credit: CDC)

Established in 2017, VALIDATE is an international network of researchers working together to accelerate vaccine development for four complex neglected intracellular pathogens that cause significant mortality and morbidity throughout the world, particularly in low and middle-income countries (LMICs): Mycobacterium tuberculosis (causing TB), Leishmania species (leishmaniasis), Burkholderia pseudomallei (melioidosis) and Mycobacterium leprae (leprosy). A second, important aim of the VALIDATE Network is to facilitate career progression for its members, particularly Early Career Researchers, researchers from LMICs, and researchers identifying as female.


VALIDATE connects over 650 members from almost 300 institutes across 74 countries, increasing collaboration among its membership, and increasing information dissemination across different research disciplines, countries, institutes, both target and model species, and across our focus pathogens; we have a multidisciplinary and One Health approach. We provide this central hub website, which highlights grants, jobs and training opportunities in our research field, as well as shared SOPs and data-sets; award Fellowship, pump-priming, training and travel grants; organise events, including an Annual Meeting, workshops, research seminars, public lectures and school talks; and have mentoring and equipment exchange schemes. To date, the VALIDATE Network and our various activities have facilitated over 100 new collaborations, 63 peer-reviewed publications, and attracted £13.8M in follow-on funding.


The VALIDATE Network is led by Director Prof Helen McShane (University of Oxford, UK) and co-Director Prof Samantha Sampson (Stellenbosch University, South Africa), with Executive Manager & Co-Investigator Samantha Vermaak (University of Oxford, UK). Membership is free and open to all - to find out more (and to join VALIDATE) just look around on this website, or get in touch with our team at VALIDATE@ndm.ox.ac.uk.


Our Aims

  • Accelerate vaccine R&D for TB, leishmaniasis, melioidosis, and leprosy
  • Create an engaged and interactive international research community of members all working towards efficacious vaccines for our focus pathogens
  • Create new cross-pathogen, cross-continent, cross-species, and cross-discipline research collaborations
  • Fund important research via Pump-priming and Fellowship grants
  • Facilitate CPD and career progression for our members, particularly early career and LMIC researchers
  • Provide useful and relevant information to our Members about research, and funding and CPD opportunities
  • Influence government, funders and the media on the importance of vaccine development for these pathogens
  • Help interested people in the general public find out more about our research and the diseases we’re tackling in an accessible format